Immunoglobulin-mediated membranoproliferative glomerulonephritis
MONDO:0014005Glomerulonephritis characterized by mesangial proliferation, endocapillary proliferation, and glomerular capillary wall remodeling with immune complex deposits from classical complement pathway activation.
Also known as: Ig-mediated MPGN, Ig-mediated membranoproliferative glomerulonephritis, NPHS7, immune complex mediated membranoproliferative glomerulonephritis, immunoglobulin-mediated MPGN, immunoglobulin-mediated membranoproliferative glomerulonephritis, membranoproliferative glomerulonephritis type I, mesangiocapillary glomerulonephritis type 1
19 clinical trials for this condition and its sub-types, 12 tagged with Immunoglobulin-mediated membranoproliferative glomerulonephritis itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
New drug aims to stop kidney disease from coming back after transplant
Disease control CompletedThis phase 2 study tested a drug called pegcetacoplan in 13 kidney transplant patients whose original kidney disease (C3G or IC-MPGN) had come back. The goal was to see if the drug could reduce signs of disease activity in the kidney. The study was small and early-stage, so resul…
Phase 2 • Sponsor: Apellis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Hope for rare kidney patients: new drug shows promise in phase 3 trial
Disease control CompletedThis study tested a drug called pegcetacoplan in 124 adults and teens with two rare kidney diseases (C3G and IC-MPGN). The goal was to see if the drug could reduce protein in the urine, a sign of kidney damage. Participants received either the drug or a placebo twice a week for 2…
Phase 3 • Sponsor: Apellis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC